HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ching Feng Weng Selected Research

neferine

1/2020Reversal of doxorubicin resistance in lung cancer cells by neferine is explained by nuclear factor erythroid-derived 2-like 2 mediated lung resistance protein down regulation.
5/2017Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).
1/2017Neferine Potentiates the Antitumor Effect of Cisplatin in Human Lung Adenocarcinoma Cells Via a Mitochondria-Mediated Apoptosis Pathway.
6/2014Doxorubicin induced apoptosis was potentiated by neferine in human lung adenocarcima, A549 cells.
1/2014Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest.
12/2013Neferine from Nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ching Feng Weng Research Topics

Disease

6Neoplasms (Cancer)
01/2020 - 12/2013
4Lung Neoplasms (Lung Cancer)
01/2020 - 12/2013
2Cardiotoxicity
01/2020 - 06/2014
2Adenocarcinoma of Lung
05/2017 - 01/2017

Drug/Important Bio-Agent (IBA)

6neferineIBA
01/2020 - 12/2013
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2020 - 06/2014
2Cisplatin (Platino)FDA LinkGeneric
05/2017 - 01/2017
2AlkaloidsIBA
01/2017 - 01/2014
1Glutathione (Reduced Glutathione)IBA
01/2020
1major vault proteinIBA
01/2020
1Beclin-1IBA
05/2017
1Antineoplastic Agents (Antineoplastics)IBA
06/2014

Therapy/Procedure

3Drug Therapy (Chemotherapy)
05/2017 - 01/2014
1Therapeutics
05/2017